De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.

IF 6.4 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2025-04-05 DOI:10.1038/s41416-025-02994-7

Bima J Hasjim, Arsha Ostowari, Monique Gandawidjaja, Mohsen D Mohammadi, Linda Suk-Ling Murphy, Matthew D Whealon, Valery Vilchez, Hirohito Ichii, Robert R Redfield, Oliver S Eng

{"title":"De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.","authors":"Bima J Hasjim, Arsha Ostowari, Monique Gandawidjaja, Mohsen D Mohammadi, Linda Suk-Ling Murphy, Matthew D Whealon, Valery Vilchez, Hirohito Ichii, Robert R Redfield, Oliver S Eng","doi":"10.1038/s41416-025-02994-7","DOIUrl":null,"url":null,"abstract":"Background: Kidney transplant (KT) patients have higher risks of developing de novo colorectal cancer (CRC) compared to the general population. However, there is still a knowledge gap in their clinical characteristics, as most single- or multi-center efforts are underpowered and lack generalizability.Methods: PubMed, Web of Science, Cochrane CENTRAL, and Scopus databases were queried for studies published until July 22nd, 2024. Studies reporting the clinicopathologic characteristics and outcomes of de novo CRC among KT recipients were included.Results: There were 49 articles included involving 1855 KT patients who developed CRC. The mean time from transplantation to CRC diagnosis was 8·7 years (95%CI 7·2, 10·3 years; I2 = 98·3%). De novo CRC was most commonly located in the ascending colon (43·6%; 95%CI 29·5%, 58·9%; I2 = 55·3%), and 37·1% had advanced CRC at diagnosis (95%CI 22·3%, 54·8%; I2 = 64·1%). Although 68·8% underwent curative intent treatment (95%CI 45·4%, 85·4%; I2 = 65·4%), pooled 5-year survival rate was 31·8% (95%CI 10·5%, 65·1%; I2 = 82·5%).Conclusions: De novo CRC was diagnosed in under 10 years after KT, and nearly 40% of patients already have advanced stage disease at diagnosis. The pooled rate of 5-year survival was 31.8%. However, there was wide heterogeneity between studies and further research is required. PROSPERO Registration: CRD42023415767.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-025-02994-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Kidney transplant (KT) patients have higher risks of developing de novo colorectal cancer (CRC) compared to the general population. However, there is still a knowledge gap in their clinical characteristics, as most single- or multi-center efforts are underpowered and lack generalizability.

Methods: PubMed, Web of Science, Cochrane CENTRAL, and Scopus databases were queried for studies published until July 22^nd, 2024. Studies reporting the clinicopathologic characteristics and outcomes of de novo CRC among KT recipients were included.

Results: There were 49 articles included involving 1855 KT patients who developed CRC. The mean time from transplantation to CRC diagnosis was 8·7 years (95%CI 7·2, 10·3 years; I² = 98·3%). De novo CRC was most commonly located in the ascending colon (43·6%; 95%CI 29·5%, 58·9%; I² = 55·3%), and 37·1% had advanced CRC at diagnosis (95%CI 22·3%, 54·8%; I² = 64·1%). Although 68·8% underwent curative intent treatment (95%CI 45·4%, 85·4%; I² = 65·4%), pooled 5-year survival rate was 31·8% (95%CI 10·5%, 65·1%; I² = 82·5%).

Conclusions: De novo CRC was diagnosed in under 10 years after KT, and nearly 40% of patients already have advanced stage disease at diagnosis. The pooled rate of 5-year survival was 31.8%. However, there was wide heterogeneity between studies and further research is required. PROSPERO Registration: CRD42023415767.

查看原文本刊更多论文

肾移植术后新发结直肠癌：一项系统综述和荟萃分析。

背景：与普通人群相比，肾移植（KT）患者发生新发结直肠癌（CRC）的风险更高。然而，由于大多数单中心或多中心的研究力度不足，缺乏普遍性，因此在其临床特征方面仍存在知识差距。方法：检索PubMed、Web of Science、Cochrane CENTRAL和Scopus数据库，检索截止到2024年7月22日发表的研究。研究报告了KT受体中新发CRC的临床病理特征和结果。结果：纳入49篇文献，涉及1855例发展为结直肠癌的KT患者。从移植到CRC诊断的平均时间为8.7年(95%CI为7.2,10.3年；i2 = 98·3%)。新生结直肠癌最常见于升结肠(43.6%；95%ci 29.5%, 58.9%；I2 = 55.3%)， 37.1%在诊断时为晚期CRC (95%CI 22.3%, 54.8%；i2 = 64·1%)。虽然68.8%的人接受了治愈性治疗(95%CI为45.4%,85.4%；I2 = 65.4%)，合并5年生存率为31.8% (95%CI 10.5%, 65.1%；i2 = 82.5%)。结论：在KT后不到10年的时间里，有近40%的患者在诊断时已经处于晚期。5年总生存率为31.8%。然而，研究之间存在广泛的异质性，需要进一步的研究。普洛斯彼罗注册号：CRD42023415767。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.